

Global Life Sciences Fund I2 HSGD

Fund facts at 30 September 2020 Date of issue: 13 October 2020

Structure

Irish Investment Company

Fund launch date

31 March 2000

Share class launch date

04 June 2019

Base currency

USD

Fund size (USD)

3.14bn

Benchmark

MSCI World Health Care

Fund managers

Andy Acker, CFA

NAV (SGD)

12.66

Maximum initial charge

2.00%

Annual management charge (AMC)

1.50% pa

Total expense ratio (TER)

1.59%

Codes

ISIN: IE00BJJMRZ35

Sedol: BJJMRZ3

Objective and investment policy

The Fund aims to provide capital growth over the long term.

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Additional information


The MSCI World Healthcare index is a reference benchmark for performance reporting only.

Information relating to other currencies and fee structure can be found in the fund prospectus.

Refer to Annual Report and Accounts for more information on fees and expenses, AMC included.

Performance in (SGD)

Percentage growth, 05 Jun 2019 to 30 Sep 2020.



■ Janus Henderson Global Life Sciences Fund I2 HSGD (26.6%)

Annualised performance %	I2	I2 (with sales charge)^
1 month	-0.8	-2.8
3 months	4.5	2.5
6 months	26.7	24.2
YTD	8.3	6.1
1 year	28.3	25.7
3 years (p.a)	-	-
5 years (p.a)	-	-
10 years (p.a)	-	-
Since inception 04 Jun 2019 (p.a)	19.5	17.1

Source: at 30 Sep 2020. © 2020 Morningstar. All rights reserved, performance is net of fees, with gross income reinvested. Performance figures of less than 1 year are not annualized.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Past performance is not a guide to future performance.

Global Life Sciences Fund I2 HSGD

Top 10 holdings	(%)	Industry breakdown	(%)	Market capitalisation	(%)
Merck & Co Inc	3.7	Pharmaceuticals	33.6	Over \$100B	38.2
UnitedHealth Group Inc	3.5	Biotechnology	32.5	\$50B to \$100B	11.9
Novartis AG (ADR)	3.4	Health Care Equipment	14.3	\$10B to \$50B	19.2
Thermo Fisher Scientific Inc	3.1	Managed Health Care	8.5	\$5B to \$10B	8.4
Roche Holding AG	3.0	Life Sciences Tools &	5.7	\$1B to \$5B	12.8
AbbVie Inc	3.0	Services		\$500M to \$1B	2.9
AstraZeneca PLC	3.0	Health Care Supplies	3.2	\$250M to \$500M	0.1
Abbott Laboratories	2.6	Health Care Services	1.0	N/A	6.2
Humana Inc	2.6	Health Care Technology	0.7		
Boston Scientific Corp	2.4	Health Care Facilities	0.2		
Total number of positions	120				

What are the risks specific to this fund?

- The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
- Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.

General risks

- Past performance is not a guide to future performance.
- The value of an investment and income can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at www.janushenderson.com/sg

Global Life Sciences Fund I2 HSGD

Janus Henderson
INVESTORS

Important information

^Performance with sales charge assume 2.00% initial sales charge/front-end load (FEL) applied. For hedged share classes the appropriate index is the hedged version of the mandated benchmark. Only share class returns are displayed as we do not currently subscribe to this index. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. Source: Janus Henderson Investors unless stated otherwise. This document has been prepared by Janus Henderson Investors (Singapore) Limited, the Singapore Representative of the Fund. The Fund is distributed by authorised distributors. The prospectus and Product Highlights Sheet ("PHS") of the Fund are available and may be obtained from the Singapore Representative's office and the authorized distributors' offices. Investors should read the prospectus and PHS before deciding whether to invest in the shares of the Fund. The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments. Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Janus Capital International Limited acts as the investment adviser to JHCF. Janus Capital Management LLC ("Janus") acts as sub-investment adviser of the Fund to Janus Capital International Limited. This is neither an offer nor solicitation to purchase Shares of the Fund. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from all distributors and paying agents, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions. In particular, it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of information available from public sources. Unless otherwise stated, the source of information is from Janus Henderson Investors. It is the intermediary's responsibility to determine the extent it may pass on this document or the information contained in it to any third party under relevant law, and to comply with all such law. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties. Investments are not deposits or other obligations of, guaranteed or insured by Janus Capital International Limited or any distributor or any of their affiliates, or by any local governmental or insurance agency. Dividend amount or dividend rate is not guaranteed. Positive dividend does not mean positive return. Bond credit quality ratings provided by Barclays and reflect the middle rating received from Moody's, Standard & Poor's and Fitch, where all three agencies have provided a rating. If only two agencies rate a security, the lowest rating is used. If only one agency rates a security, that rating is used. Ratings are measured on a scale that ranges from Aaa (highest) to D (lowest). Portfolio holdings are subject to change without notice. ©2019 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. © 2019, Janus Henderson Group plc. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. The Fund may at its discretion (i) pay dividends out of the capital of the Fund, and (ii) pay dividends out of gross income while charging all or part of the fees and expenses to the capital of the Fund, resulting in an increase in distributable income available for the payment of dividends by the Fund and therefore, the Fund may effectively pay dividends out of capital. This may result in an immediate reduction of the Fund's net asset value per share, and it amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Past distributions are not necessarily indicative of future trends, which may be lower. The distribution frequency and details can be obtained at the website www.janushenderson.com/sg. Janus Henderson Investors (Singapore) Limited. Address: 138 Market Street, #34-03/04, CapitaGreen, Singapore 048946 Website: www.janushenderson.com/sg Company Registration No. 199700782N. **This advertisement has not been reviewed by the Monetary Authority of Singapore.**